Fed Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2005-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study was to investigate the bioequivalence of Mylan's topiramate sprinkle 25 mg capsules to Ortho-McNeil's Topamax® Sprinkle 25 mg capsules following a single, oral 25 mg (1 x 25 mg) dose administered under fed conditions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Topiramate 25 mg Capsules Under Fed Conditions

NCT00904943

Healthy

COMPLETED PHASE1

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fed Conditions

NCT00939705

Healthy

COMPLETED PHASE1

Bioequivalence Study of Topiramate Tablets 25mg Under Fed Conditions

NCT00902473

Healthy

COMPLETED NA

Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted Conditions

NCT00939692

Healthy

COMPLETED PHASE1

Topiramate 25 mg Tablets Under Fed Conditions

NCT00905567

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Topiramate Sprinkle Capsules 25 mg

Group Type EXPERIMENTAL

Topiramate Sprinkle Capsules 25 mg

Intervention Type DRUG

25mg, single dose fed

2

Topamax® Sprinkle Capsules 25 mg

Group Type ACTIVE_COMPARATOR

Topamax® Sprinkle Capsules 25 mg

Intervention Type DRUG

25mg, single dose fed

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Topiramate Sprinkle Capsules 25 mg

25mg, single dose fed

Intervention Type DRUG

Topamax® Sprinkle Capsules 25 mg

25mg, single dose fed

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy, adult subjects, 18 years and older
* able to swallow medication

Exclusion Criteria

* institutionalized subjects
* history of any significant disease
* use of any prescription or OTC medications within 14 days of start of study
* received any investigational products within 30 days prior to start of study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes